Loading...
Syngene International Community
NSEI:SYNGENE Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
Community Investing Ideas
Dedicated Peptide Lab And Global Facilities Will Unlock Biopharma Potential
Key Takeaways Expansion in biologics, digitalization, and new manufacturing assets enhances revenue growth, margin improvement, and market share in both Indian and US markets. Deep industry partnerships, outsourcing trends, and regulatory credibility ensure sustained growth momentum, robust client wins, and long-term business stability.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
₹715.63
8.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
13.96% p.a.
Profit Margin
12.34%
Future PE
60.65x
Share price in 2028
₹1.03k